Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

NCT03467958 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT03467958
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03467958 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
Lead sponsor
Celgene
Phase
Phase 3
Overall status
Terminated
Start date
August 24, 2018
Completion date
October 31, 2024
Enrollment
854 (actual)
Sites
766

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease